Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Pathological Findings
Representative light micrographs of allografts from the nontreated group and the clarithromycin (CAM)-treated group. (A) Representative pathological findings with hematoxylin and eosin (HE) (a, b, e, and f) and Mallory (c, d, g, and h) stain in full allomismatch allografts. Although myocardial cell infiltration and fibrosis were observed in nontreatment (a, c, e, and g) on day 7, the CAM treatment (b, d, f, and h) markedly attenuated them. Scale bars = 2 mm (a to d) and 50 µm (e to h). (B) Representative pathological findings with HE (a and b), Mallory (c and d), and Elastica van Gieson (EvG) (e and f) stain in class II mismatch allografts. Although myocardial cell infiltration, fibrosis, and graft arterial disease (GAD) were observed in the nontreated allografts (a, c, and e) on day 60, CAM treatment (b, d, and f) markedly attenuated them. Scale bars = 2 mm (a to d) and 25 µm (e and f). (C) Quantitative data of cell infiltration (a) and fibrosis (b) in the full allomismatch combination. Quantitative data of cell infiltration (d), fibrosis (e) area, and percentage of neointimal thickening (c) in the class II mismatch combination. *p < 0.05 versus nontreated group.
|
